MMP9

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Retrieved on: 
星期五, 六月 9, 2023
PIM1, Ruxolitinib, ASH, European Hematology Association, Diarrhea, JAK, DLT, Trae tha Truth, Toxicity, MF, TSS, Congress, Fibrosis, MMP9, Spleen, Patient, BID, SVR, EHA, Nausea, Cytokine, Society, Pharmaceutical industry

Initial preliminary data was presented at American Society of Hematology (ASH) Annual Meeting & Exposition 2022 .

Key Points: 
  • Initial preliminary data was presented at American Society of Hematology (ASH) Annual Meeting & Exposition 2022 .
  • Updated results were presented in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress, being held June 8-11, 2023 in Frankfurt, Germany as well as virtually on the Congress platform from June 8-11, 2023.
  • Preliminary data of TP-3654 monotherapy in relapsed/refractory myelofibrosis (MF) patients showed spleen volume reduction (SVR), and total symptom score (TSS) improvement.1 Further, TP-3654 may prompt early cytokine changes that may correlate with symptoms response.
  • "We are encouraged by these preliminary clinical data and are pleased that in dose ranges evaluated to date, TP-3654 has been well-tolerated with no myelosuppressive treatment-related adverse events (TRAEs).

FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients

Retrieved on: 
星期二, 四月 25, 2023
FDA, General Health, Health, Injection, Grey, Disability, CCL2, Quality of life, Research, Biomarker, Cerebrospinal fluid, Walking, Dementia, Tisch, MS, MMP9, Patient, B cell, Phase, Inflammation, Pharmaceutical industry, Medical device

The Phase II trial showed improvements across multiple areas in progressive MS patients with significant disability.

Key Points: 
  • The Phase II trial showed improvements across multiple areas in progressive MS patients with significant disability.
  • Additionally, patients who received the stem cell treatments showed improved bladder function, with 69% of patients showing improved post-void residual volume.
  • “These findings are unprecedented in the realm of researching stem cells as a treatment pathway for progressive MS patients.
  • The Phase II trial began in 2018 and was a randomized, double-blind, placebo-controlled clinical study with 54 patients.

Pipeline Review for Matrix Metalloproteinase 9 - H2 2020 - ResearchAndMarkets.com

Retrieved on: 
星期二, 二月 9, 2021
Health, Other Health, Matrix metalloproteinases, Branches of biology, Gelatinase B, Metalloproteins, Protein families, MMP9, Gelatinase A, Proteins, Matrix metalloproteinase, Biology, Osteoclast, Gelatinase

The "Matrix Metalloproteinase 9 - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Matrix Metalloproteinase 9 - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family.
  • It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption.
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 16 molecules.